CN107056899A - A kind of cell membrane localization signal peptide and its encoding gene and application - Google Patents
A kind of cell membrane localization signal peptide and its encoding gene and application Download PDFInfo
- Publication number
- CN107056899A CN107056899A CN201710398887.8A CN201710398887A CN107056899A CN 107056899 A CN107056899 A CN 107056899A CN 201710398887 A CN201710398887 A CN 201710398887A CN 107056899 A CN107056899 A CN 107056899A
- Authority
- CN
- China
- Prior art keywords
- cell membrane
- signal peptide
- cell
- protein
- target
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 59
- 210000000170 cell membrane Anatomy 0.000 title claims abstract description 52
- 108010076504 Protein Sorting Signals Proteins 0.000 title claims abstract description 39
- 230000004807 localization Effects 0.000 title claims abstract description 29
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 37
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 20
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 14
- 241000894006 Bacteria Species 0.000 claims abstract description 12
- 229920001184 polypeptide Polymers 0.000 claims abstract description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 8
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 5
- 239000006143 cell culture medium Substances 0.000 claims abstract description 4
- 208000015181 infectious disease Diseases 0.000 claims abstract description 4
- 244000045947 parasite Species 0.000 claims abstract description 4
- 238000006467 substitution reaction Methods 0.000 claims abstract description 4
- 229960005486 vaccine Drugs 0.000 claims abstract description 4
- 241000700605 Viruses Species 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 39
- 239000002773 nucleotide Substances 0.000 claims description 12
- 125000003729 nucleotide group Chemical group 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 7
- 230000004927 fusion Effects 0.000 claims description 6
- 230000006798 recombination Effects 0.000 claims description 3
- 238000005215 recombination Methods 0.000 claims description 3
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 238000009396 hybridization Methods 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 238000003259 recombinant expression Methods 0.000 claims description 2
- 230000009261 transgenic effect Effects 0.000 claims description 2
- 238000011144 upstream manufacturing Methods 0.000 claims description 2
- 230000003834 intracellular effect Effects 0.000 abstract description 6
- 230000008685 targeting Effects 0.000 abstract description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 3
- 230000002018 overexpression Effects 0.000 abstract description 3
- 150000001413 amino acids Chemical class 0.000 abstract description 2
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 230000014616 translation Effects 0.000 abstract description 2
- 239000013612 plasmid Substances 0.000 description 30
- 230000029087 digestion Effects 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 13
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 238000012408 PCR amplification Methods 0.000 description 8
- 108091008146 restriction endonucleases Proteins 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 5
- 101710149951 Protein Tat Proteins 0.000 description 5
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 5
- 229920001601 polyetherimide Polymers 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000008499 blood brain barrier function Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- XZFYRXDAULDNFX-UHFFFAOYSA-N N-L-cysteinyl-L-phenylalanine Natural products SCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XZFYRXDAULDNFX-UHFFFAOYSA-N 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000009465 prokaryotic expression Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
- GIVWETPOBCRTND-DCAQKATOSA-N Arg-Gln-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O GIVWETPOBCRTND-DCAQKATOSA-N 0.000 description 1
- BTJVOUQWFXABOI-IHRRRGAJSA-N Arg-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCNC(N)=N BTJVOUQWFXABOI-IHRRRGAJSA-N 0.000 description 1
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 1
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- TUIOUEWKFFVNLH-DCAQKATOSA-N Leu-Val-Cys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(O)=O TUIOUEWKFFVNLH-DCAQKATOSA-N 0.000 description 1
- CTJUSALVKAWFFU-CIUDSAMLSA-N Lys-Ser-Cys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N CTJUSALVKAWFFU-CIUDSAMLSA-N 0.000 description 1
- MDHZEOMXGNBSIL-DLOVCJGASA-N Phe-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N MDHZEOMXGNBSIL-DLOVCJGASA-N 0.000 description 1
- UXQFHEKRGHYJRA-STQMWFEESA-N Phe-Met-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(=O)NCC(O)=O UXQFHEKRGHYJRA-STQMWFEESA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 102100025292 Stress-induced-phosphoprotein 1 Human genes 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 108010068380 arginylarginine Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses a kind of cell membrane localization signal peptide and its encoding gene and application, described signal peptide is (a) or (b)；(a) polypeptide being made up of the amino acid sequence shown in SEQ ID NO.1；(b) substitution by the amino acid sequence shown in SEQ ID NO.1 by one or several amino acid residues and/or missing and/or addition and the derivative polypeptide with cell membrane localization signal peptide function.The present invention is another on the basis of the DNA sequence dna of coding Tat basic domains to have added 11 amino acid codings, and the targeting of endogenous and external source target protein can be positioned at cell membrane by the cell membrane localization signal peptide of formation.The cell membrane localization signal peptide that the present invention is provided and suitable target protein formation fusion protein, it is added to by intracellular overexpression or external source in cell culture medium, enhance the validity of endogenous and foreign protein cell membrane targeting positioning, the vaccine and medicine of virus, parasite, bacterium infection are treated available for exploitation, and realizes efficiently administration.
Description
Technical field
The present invention relates to a kind of cell membrane localization signal peptide, encoding gene and its application, belong to gene engineering technology field.
Background technology
Many human diseases, including nerve degenerative diseases, are currently what be can not be cured.Cell and tissue barrier are deposited
In, such as blood-brain barrier (blood-brain barrier, BBB) under neurodegenerative disease particular case, treatment point is prevented
The targeting transport of son, reduces the ability that treatment molecule reaches its own target.By with that can be worn through the cell of biomembrane
The combination of saturating peptide (cell-penetrating peptides, CPP) is the heat of research with the bio distribution for increasing tissue treatment agent
Point.CPP can carry different treatment molecules, be transported to their specific target spot and increase them them and be difficult to approach
Tissue in concentration, so as to strengthen their therapeutic efficiency.
It is most to have prospect at present from the polypeptide of HIV-1 transcription factor Tat albumen basic domains, studies most clear
CPP.It is expected to be used for treating various human diseases, particularly nerve degenerative diseases.It can be from different treatment molecule knots
Close, including small molecule, antibody, polypeptide, liposome, nano particle and nucleic acid etc.；It can be effectively increased the tissue of therapeutic agent
Permeability and the efficiency for reaching biological targets.
After the DNA sequence dna of coding Tat basic domains is merged with other GFPs, being overexpressed in target cell to drive
Target protein is positioned in nucleus.And the penetrating peptide of Tat basic domains formation can be by endocytosis after being merged with foreign protein
Approach enters cytoplasm, is accumulated in cytoplasm, has fraction to enter in nucleus.Therefore, it is possible to effectively make foreign protein
The target spot acted in cytoplasm and nucleus.These characteristics of Tat basic domains, are that the new albumen of present invention identification turns
Fortune signal peptide is laid a good foundation.The Protein transport signal peptide can drive fusion protein to be positioned on cell membrane, strengthen it is endogenous and
The validity of foreign protein cell membrane targeting positioning.
The content of the invention
In order to solve the above problems, it is an object of the invention to provide a kind of cell membrane localization signal peptide, encoding gene and its
Using endogenous (intracellular to be overexpressed) and the targeting of external source target protein can be positioned at cell membrane by the cell membrane localization signal peptide.
To achieve these goals, the technical solution adopted in the present invention is：
A kind of cell membrane localization signal peptide, described signal peptide is (a) or (b)；
(a) polypeptide being made up of the amino acid sequence shown in SEQ ID NO.1；
(b) by the amino acid sequence shown in SEQ ID NO.1 is by the substitution of one or several amino acid residues and/or lacks
Lose and/or addition and the derivative polypeptide with cell membrane localization signal peptide function.
A kind of gene order of cell membrane localization signal peptide described in coding, described gene order is (a), (b) or
(c)；
(a) nucleotide sequence as shown in SEQ ID NO.2；
(b) under strict conditions with the nucleotide sequence hybridization shown in SEQ ID NO.2 and coding have cell membrane localization
The nucleotide sequence of signal peptide functional protein；
(c) there is more than 90% homology with the nucleotide sequence shown in SEQ ID NO.2 and encode and determine with cell membrane
The nucleotide sequence of position signal peptide functional protein.
A kind of recombination fusion protein containing described cell membrane localization signal peptide.
A kind of recombinant expression carrier containing described gene order, recombinant bacterium or transgenic cell line.
A kind of described signal peptide is in the application that target protein is positioned in cell membrane.
A kind of method that target protein is positioned to cell membrane, will using described signal peptide as cell membrane localization signal peptide
Target protein is positioned on cell membrane.
The described method that target protein is positioned to cell membrane, comprises the following steps：
(a) fusion is imported in target cell, so that target protein is positioned on the cell membrane of target cell；It is described to melt
Close gene includes the gene order of encoded signal peptide and the gene order of encoding target albumen successively from upstream to downstream；Or
(b) external source fusion protein is added in target cell culture medium, so that cell membrane of the target protein across target cell
It is positioned at into target cell, and finally on the cell membrane of target cell；The external source fusion protein includes successively from N-terminal to C-terminal
The amino acid sequence of cell membrane localization signal peptide and target protein.
Described target cell is HeLa cells.
A kind of described cell membrane localization signal peptide is preparing the vaccine and medicine for the treatment of virus, parasite, bacterium infection
In application.
Beneficial effects of the present invention：
The present invention has separately added 11 amino acid codings on the basis of the DNA sequence dna of coding Tat basic domains, is formed
Cell membrane localization signal peptide endogenous (intracellular be overexpressed) and external source target protein can be targetted and be positioned at cell membrane.This is sent out
The cell membrane localization signal peptide of bright offer and suitable target protein formation fusion protein, are added by intracellular overexpression or external source
Enter into cell culture medium, enhance the validity of endogenous and foreign protein cell membrane targeting positioning, available for exploitation treatment disease
Poison, parasite, the vaccine and medicine of bacterium infection, and realize efficiently administration.
Brief description of the drawings
Fig. 1 is the recombinant plasmid pcDNA3.1-21aa-EGFP of present invention Vector map.
The result figure that Fig. 2 builds for the recombinant plasmid pcDNA3.1-21aa-EGFP of the present invention, swimming lane 1,2 is attached most importance to
Group plasmid pcDNA3.1-21aa-EGFP.
The fusion protein that Fig. 3 is expressed after the recombinant plasmid pcDNA3.1-21aa-EGFP transfection HeLa cells for the present invention
Detection and localization figure.
Fig. 4 is recombinant plasmid pET-28a (+) -21aa-EGFP of present invention Vector map.
Fig. 5 is the result figure of recombinant plasmid pET-28a (+) -21aa-EGFP structures of the present invention, and swimming lane 1,2 is
Recombinant plasmid pET-28a (+) -21aa-EGFP.
Detection and localization figures of the Fig. 6 for exogenous recombinant protein His-21aa-EGFP of the invention in HeLa cells.
Embodiment
Following examples facilitate a better understanding of the present invention, but do not limit the present invention.Experiment side in following embodiments
Method, is conventional method unless otherwise specified.Test material used, is from routine biochemistry reagent business unless otherwise specified
Shop is commercially available.
Embodiment 1, the positioning in the intracellular overexpression fusion proteins of HeLa
First, the structure of eukaryotic expression recombination plasmid
1st, primer is designed
Synthesized by Shanghai Sheng Gong Bioisystech Co., Ltd comprising (the SEQ ID of expressed sequence table shown in SEQ ID NO.2
NO.1 is from the polypeptide of the 1st to 21 amino acid residues of N-terminal composition, abbreviation 21aa) nucleotide sequence pcr amplification primer thing,
Specially：
Sense primer 21For：5’-CTGGTACCATGAAGTCGTGCTTCGCATGCCTAGTCTGCTTCATGGG
It is Kpn I restriction enzyme sites at ACGTAAGAAGCGACGACAGCGACGACGAGTGAGCAAGGGCGAGGAGC-3 ', underscore
(SEQ ID NO.3)；
Anti-sense primer 21Rev：5’-CTGAATTCIt is EcoR I digestions position at TTACTTGTACAGCTCGTC-3 ', underscore
Point (SEQ ID NO.4).
2nd, PCR is expanded：Using plasmid pEGFP-N1 as template, enter performing PCR amplification, obtain the PCR primer that size is 799bp.
PCR amplification system (50 μ l) is：10×buffer 5μl、MgCl2(25mM)5μl、dNTP mixture(10mM each)1μl、
The 11 μ l of μ l, 21Rev (10 μM) of μ l, 21For (10 μM) of Taq polymerase (5U/ μ l) 0.5, the μ l of template 1, remaining addition
ddH2O.PCR amplification conditions are：94℃5min；94 DEG C of 30s, 56 DEG C of 30s, 72 DEG C of 60s, 30 circulations；72℃10min.
3rd, digestion：With the PCR primer (37 DEG C of digestion 4h) in restriction enzyme Kpn I and EcoR I double digestion steps 2,
Obtain PCR digestion products.Meanwhile, with restriction enzyme Kpn I and EcoR I double digestion plasmid pcDNA3.1 (+), reclaim
5400bp or so linear plasmid DNA segment.
4th, connect：The PCR digestion products of step 3 and pcDNA3.1 (+) linear DNA fragment are connected, recombinant plasmid is obtained
PcDNA3.1-21aa-EGFP, pcDNA3.1-21aa-EGFP plasmid map are shown in Fig. 1.Recombinated with Kpn I and EcoR I double digestions
Plasmid pcDNA3.1-21aa-EGFP, obtains the DNA segment (Fig. 2) of the 799bp described in step 2.According to sequencing result, counterweight
Group plasmid pcDNA3.1-21aa-EGFP architectural feature is described as：In plasmid pcDNA3.1 (+) Kpn I and EcoR I digestions
What the gene order of gene order and encoding green fluorescent protein EGFP between site shown in insertion SEQ ID NO.2 was constituted
Fragment is merged, 21aa and EGFP fusion protein, abbreviation 21aa-EGFP is expressed.
2nd, positioning of the fusion protein in HeLa cells
With recombinant plasmid pcDNA3.1-21aa-EGFP transfection HeLa cells, determining for HeLa intracellular fusion proteins is detected
Position.Specific method is：
1st, the culture of HeLa cells：Cultured HeLa cells are digested to 0.25% pancreatin it is unicellular, with containing
It is 1.5 × 10 that the DMEM culture mediums of 10% hyclone, which are resuspended to cell concentration,5Cells/ml, is inoculated to 12 hole cell culture
In plate, 1ml/ holes, in 35 DEG C, 5%CO2Under the conditions of culture 18-24h to cell attachment, during transfection, cell density is with 70-80%
It is advisable.
2nd, DNA/PEI mixtures are prepared：With the DMEM culture mediums without serum and antibiotic, by every 1 μ g recombinant plasmids
PcDNA3.1-21aa-EGFP is diluted to 90 μ l；6 μ l 1mg/ml PEI (polyetherimides are added according still further to every 1 μ g recombinant plasmids
Amine) ratio of solution adds PEI solution, gentle to mix, and is stored at room temperature 10min.
3rd, transfect：The old culture medium in Tissue Culture Plate is discarded, 900 μ l fresh cultures are added per hole and (contain 10% tire ox
The DMEM culture mediums of serum)；The DNA/PEI mixtures being incubated are added to cell according to the amount of every μ g recombinant plasmids of hole 1 and trained
It is gentle to mix in each hole for supporting plate, in 35 DEG C, 5%CO2Under the conditions of continue cultivate；After 18-24h, marked with Hoechst dye liquors
The positioning of measurement fusion albumen, is as a result shown in Fig. 3 under nucleus, fluorescence microscope.Fig. 3 results show, fusion protein 21aa-EGFP
On the cell membrane for being primarily located within HeLa cells.
The positioning of embodiment 2, exogenous fusion protein in HeLa cells
First, the structure of RT-PCR expression plasmid
1st, primer is designed
Synthesized by Shanghai Sheng Gong Bioisystech Co., Ltd comprising (the SEQ ID of expressed sequence table shown in SEQ ID NO.2
NO.1 is from the polypeptide of the 1st to 21 amino acid residues of N-terminal composition, abbreviation 21aa) nucleotide sequence pcr amplification primer thing,
Specially：
The For of sense primer 21 '：
5’-CTGGATCCATGAAGTCGTGCTTCGCATGCCTAGTCTGCTTCATGGGACGTAAGAAGCGACGACAGC
It is BamH I restriction enzyme sites (SEQ ID NO.5) at GACGACGAGTGAGCAAGGGCGAGGAGC-3 ', underscore；
The Rev of anti-sense primer 21 '：5’-GACTCGAGIt is Xho I restriction enzyme sites at CTTGTACAGCTCGTC-3 ', underscore
(SEQ ID NO.6)。
2nd, PCR is expanded：Using plasmid pEGFP-N1 as template, enter performing PCR amplification, obtain the PCR primer that size is 799bp.
PCR amplification system (50 μ l) is：10×buffer 5μl、MgCl2(25mM)5μl、dNTP mixture(10mM each)1μl、
The μ l of Taq polymerase (5U/ μ l) 0.5, the μ l of 21 ' For (10 μM) 1, the μ l of 21 ' Rev (10 μM) 1, the μ l of template 1, remaining addition
ddH2O.PCR amplification conditions are：94℃5min；94 DEG C of 30s, 56 DEG C of 30s, 72 DEG C of 60s, 30 circulations；72℃10min.
3rd, digestion：With the PCR primer (37 DEG C of digestion 4h) in restriction enzyme BamH I and Xho I double digestion steps 2,
Obtain PCR digestion products.Meanwhile, with restriction enzyme BamH I and Xho I double digestion plasmid pET-28a (+), reclaim
5300bp or so linear plasmid DNA segment.
4th, connect：The PCR digestion products of step 3 and pET-28a (+) linear DNA fragment are connected, prokaryotic expression weight is obtained
Group plasmid pET-28a (+) -21aa-EGFP, prokaryotic expression His-21aa-EGFP fusion proteins.pET-28a(+)-21aa-EGFP
Plasmid map is shown in Fig. 4.During with BamH I and Xho I double digestions pET-28a (+) -21aa-EGFP plasmids, obtain described in step 2
799bp DNA segment (Fig. 5).According to sequencing result, the architectural feature to recombinant plasmid pET-28a (+) -21aa-EGFP is retouched
State for：The gene order shown in SEQ ID NO.2 is inserted between plasmid pET-28a (+) BamH I and Xho I restriction enzyme sites
The fusion fragment constituted with encoding green fluorescent protein EGFP gene order, expression with 6 × His labels 21aa and
EGFP fusion protein, abbreviation His-21aa-EGFP.
2nd, fusion protein His-21aa-EGFP expression and purification
1st, induced expression：Plasmid pET-28a (+) -21aa-EGFP is converted in bacterial strain E.coli BL21, chosen after 12h
The single bacterium colony of corresponding plasmid conversion is taken, 3-5ml LB culture mediums (the μ g/ml containing ampicillin 100), 37 DEG C of culture 12- is inoculated into
18h, i.e. OD600Stop culture during more than 1.5.By bacterium solution by volume 1:100 are inoculated into (benzyl containing ammonia in 200ml LB culture mediums
The μ g/ml of penicillin 100), 37 DEG C of culture 2-3h, to OD600For 0.6-0.8.The control for taking 1ml bacterium solutions to be used as before induction, in residue
IPTG is added in bacterium solution to final concentration 0.1mM, 20 DEG C of slow-speed of revolution incubated overnights are gone to.Second day, 1ml bacterium solutions are taken to be used as after induction
Control, remaining bacterium solution collects thalline in 4 DEG C of 6000rpm centrifugation 8min.
2nd, cellular lysate：The thalline of collection is resuspended in 20ml phosphate buffers (phosphate-buffered
Saline, PBS), the composition of phosphate buffer is 140mM NaCl, 10mM Na2HPO4, 2.7mM KCl, 1.8mM
KH2PO4, pH 7.3.Re-suspension liquid is in 4 DEG C of 6000rpm centrifugation 8min washing thallines.Centrifuged supernatant is abandoned, by the thalline weight after washing
It is suspended from 10ml lysis buffers (20mM Tris-HCl, pH 7.4,100mM NaCl, 100mM imidazole, 0.1%
Triton X-100,1 × protease inhibitor) in prepare thalline suspension, ultrasonication to thalline suspension becomes clear
Clearly, it is to avoid produce a large amount of foams, PMSF (phenylmethylsulfonyl fluoride) to final concentration 1mM is added in good time, to reduce the degraded of albumen.4
DEG C 14000rpm centrifugation 30min, collects supernatant, and with 0.22 μm of aperture membrane filtration removal of impurities.
3rd, affinity purification：In advance with level pad 5ml (20mM Tris-HCl, pH 7.4,100mM of 5 times of column volumes
NaCl, 100mM imidazole) in equilibrium at room temperature 1ml Ni2+Sepharose magnetic beads.The magnetic bead balanced is added to cell
Crack in supernatant, in 4 DEG C of overnight incubations, PMSF to final concentration 1mM is added in good time, to reduce the degraded of albumen.Second day, use
5ml 5mM imidazole (being dissolved in 20mM Tris-HCl, pH 7.4,500mM NaCl buffer solutions) elutions are non-specific
Adhesion protein.Respectively with 5ml 50mM, 250mM, 500mM imidazole (be dissolved in 20mM Tris-HCl, pH 7.4,
In 100mM NaCl buffer solutions) elution destination protein, merge three eluents.
4th, albumen dialysis, concentration：The concentration tube of suitable aperture filter membrane is selected according to the size of molecular weight of albumen, by eluent
Add in concentration tube, 4 DEG C of 5000rpm centrifuge 10-30min, are concentrated into below 0.5ml, add after 10ml PBS are mixed and continue
Concentration, is repeated 2-3 times.Low-temperature operation is to prevent protein degradation.
5th, protein concentration is determined
Protein concentration is determined using equation, and aids in being corrected using BSA standard items.Protein concentration=[(A280
×1.5-A260× 0.75)/extinction coefficient] × extension rate, wherein A260And A280Respectively in 260nm after protein sample dilution
Absorbance during with 280nm.
3rd, positioning of the fusion protein in HeLa cells
1st, the culture of HeLa cells
The culture of HeLa cells：Cultured HeLa cells are digested to 0.25% pancreatin it is unicellular, with containing 10%
It is 1.5 × 10 that the DMEM culture mediums of hyclone, which are resuspended to cell concentration,5Cells/ml, is inoculated to 12 porocyte culture plates
In, 1ml/ holes, in 35 DEG C, 5%CO2Under the conditions of cultivate 18-24h.
2nd, the addition of foreign protein
The old culture medium in Tissue Culture Plate is discarded, 900 μ l fresh cultures are added per hole；In each hole of Tissue Culture Plate
Middle addition destination protein is gentle to mix to final concentration 30nM, in 35 DEG C, 5%CO2Under the conditions of continue cultivate；After 12h, use
Hoechst dye liquors mark the positioning of measurement fusion albumen under nucleus, fluorescence microscope, as a result see Fig. 6.Fig. 6 results show, melt
Hop protein His-21aa-EGFP is primarily located within the cell membrane of HeLa cells.
The optimal embodiment of the present invention is the foregoing is only, for those skilled in the art, the present invention can have
Various modifications and variations.Within the spirit and principles of the invention, any modification, equivalent substitution and improvements made etc., all should
Within protection scope of the present invention.
SEQUENCE LISTING
<110>Affiliated hospital of Zhengzhou University first
<120>A kind of cell membrane localization signal peptide and its encoding gene and application
<160> 6
<170> PatentIn version 3.5
<210> 1
<211> 21
<212> PRT
<213>HIV Tat basic domains
<400> 1
Lys Ser Cys Phe Ala Cys Leu Val Cys Phe Met Gly Arg Lys Lys Arg
1 5 10 15
Arg Gln Arg Arg Arg
20
<210> 2
<211> 63
<212> DNA
<213>HIV Tat basic domains
<400> 2
aagtcgtgct tcgcatgcct agtctgcttc atgggacgta agaagcgacg acagcgacga 60
cga 63
<210> 3
<211> 93
<212> DNA
<213>Artificial sequence
<400> 3
ctggtaccat gaagtcgtgc ttcgcatgcc tagtctgctt catgggacgt aagaagcgac 60
gacagcgacg acgagtgagc aagggcgagg agc 93
<210> 4
<211> 26
<212> DNA
<213>Artificial sequence
<400> 4
ctgaattctt acttgtacag ctcgtc 26
<210> 5
<211> 93
<212> DNA
<213>Artificial sequence
<400> 5
ctggatccat gaagtcgtgc ttcgcatgcc tagtctgctt catgggacgt aagaagcgac 60
gacagcgacg acgagtgagc aagggcgagg agc 93
<210> 6
<211> 23
<212> DNA
<213>Artificial sequence
<400> 6
gactcgagct tgtacagctc gtc 23
Claims (9)
1. a kind of cell membrane localization signal peptide, it is characterised in that described signal peptide is (a) or (b)；
(a) polypeptide being made up of the amino acid sequence shown in SEQ ID NO.1；
(b) substitution by the amino acid sequence shown in SEQ ID NO.1 by one or several amino acid residues and/or missing
And/or addition and the derivative polypeptide with cell membrane localization signal peptide function.
2. a kind of gene order for encoding the cell membrane localization signal peptide described in claim 1, it is characterised in that described gene
Sequence is (a), (b) or (c)；
(a) nucleotide sequence as shown in SEQ ID NO.2；
(b) under strict conditions with the nucleotide sequence hybridization shown in SEQ ID NO.2 and coding have cell membrane localization signal
The nucleotide sequence of peptide functional protein；
(c) there is more than 90% homology with the nucleotide sequence shown in SEQ ID NO.2 and coding has cell membrane localization letter
The nucleotide sequence of number peptide functional protein.
3. a kind of recombination fusion protein of the cell membrane localization signal peptide containing described in claim 1.
4. a kind of recombinant expression carrier, recombinant bacterium or the transgenic cell line of the gene order containing described in claim 2.
5. the signal peptide described in a kind of claim 1 is in the application that target protein is positioned in cell membrane.
6. a kind of method that target protein is positioned to cell membrane, it is characterised in that using the signal peptide described in claim 1 as
Target protein is positioned on cell membrane by cell membrane localization signal peptide.
7. the method according to claim 6 that target protein is positioned to cell membrane, it is characterised in that including following step
Suddenly：
(a) fusion is imported in target cell, so that target protein is positioned on the cell membrane of target cell；The fusion base
Because including the gene order of encoded signal peptide and the gene order of encoding target albumen successively from upstream to downstream；Or
(b) external source fusion protein is added in target cell culture medium, so that target protein enters across the cell membrane of target cell
In target cell, and finally it is positioned on the cell membrane of target cell；The external source fusion protein includes cell successively from N-terminal to C-terminal
The amino acid sequence of membrane positioning signal peptide and target protein.
8. the method according to claim 7 that target protein is positioned to cell membrane, it is characterised in that described target cell
For HeLa cells.
9. the signal peptide described in a kind of claim 1 is in treatment virus, parasite, the vaccine and medicine of bacterium infection is prepared
Using.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710398887.8A CN107056899B (en) | 2017-05-31 | 2017-05-31 | Cell membrane positioning signal peptide and coding gene and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710398887.8A CN107056899B (en) | 2017-05-31 | 2017-05-31 | Cell membrane positioning signal peptide and coding gene and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107056899A true CN107056899A (en) | 2017-08-18 |
| CN107056899B CN107056899B (en) | 2020-07-17 |
Family
ID=59615337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710398887.8A Expired - Fee Related CN107056899B (en) | 2017-05-31 | 2017-05-31 | Cell membrane positioning signal peptide and coding gene and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107056899B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109575116A (en) * | 2018-11-09 | 2019-04-05 | 广东海洋大学 | A kind of mitochondria positioning leads peptide and its discovery method and application |
| CN117417407A (en) * | 2023-10-20 | 2024-01-19 | 宜兴食品与生物技术研究院有限公司 | Method for forming reversible membraneless organelle in microorganism |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103097412A (en) * | 2010-07-09 | 2013-05-08 | 克鲁塞尔荷兰公司 | Anti-human respiratory syncytial virus (RSV) antibodies and methods of use |
| CN105085641A (en) * | 2015-09-18 | 2015-11-25 | 中国水产科学研究院黄海水产研究所 | Cytomembrane positioning signal peptide and coding sequence and application thereof |
-
2017
- 2017-05-31 CN CN201710398887.8A patent/CN107056899B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103097412A (en) * | 2010-07-09 | 2013-05-08 | 克鲁塞尔荷兰公司 | Anti-human respiratory syncytial virus (RSV) antibodies and methods of use |
| CN105085641A (en) * | 2015-09-18 | 2015-11-25 | 中国水产科学研究院黄海水产研究所 | Cytomembrane positioning signal peptide and coding sequence and application thereof |
Non-Patent Citations (5)
| Title |
|---|
| HAIYAN JIA等: "Cysteine-Rich and Basic Domain HIV-1 Tat Peptides", 《BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS》 * |
| M.HUSAIN等: "ACCESSION:AAG32109", 《GENBANK》 * |
| MITOLA S等: "Identification of Specific Molecular Structures of Human", 《JOURNAL OF VIROLOGY》 * |
| 王望九等: "《医学生物学》", 30 November 2008 * |
| 王海珍等: "TAT-EGFP融合蛋白的表达及在PC12细胞的转导活性", 《第四军医大学学报》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109575116A (en) * | 2018-11-09 | 2019-04-05 | 广东海洋大学 | A kind of mitochondria positioning leads peptide and its discovery method and application |
| CN109575116B (en) * | 2018-11-09 | 2022-04-22 | 广东海洋大学 | Mitochondrial localization leader peptide and discovery method and application thereof |
| CN117417407A (en) * | 2023-10-20 | 2024-01-19 | 宜兴食品与生物技术研究院有限公司 | Method for forming reversible membraneless organelle in microorganism |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107056899B (en) | 2020-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101817482B1 (en) | Genome editing using campylobacter jejuni crispr/cas system-derived rgen | |
| CN111499765B (en) | Coronavirus fusion protein and preparation method and application thereof | |
| KR20210102882A (en) | Nucleic acid constructs and methods of use | |
| US20030211590A1 (en) | Fusion protein for use as vector | |
| Yan et al. | Multiple regions of NSR1 are sufficient for accumulation of a fusion protein within the nucleolus. | |
| CA2143308A1 (en) | Translocation signal facilitated nuclear delivery of macromolecules | |
| US10000541B2 (en) | Trail cell-penetrating peptide-like mutant MUR6 and preparation method thereof | |
| CN108752425A (en) | The method for building cell-penetrating peptide expression library using display technique of bacteriophage | |
| KR20030074702A (en) | Modular transfection systems | |
| CN107056899A (en) | A kind of cell membrane localization signal peptide and its encoding gene and application | |
| CN114317609A (en) | Viral vectors and uses thereof | |
| CA2939541C (en) | Hybrid proteins and uses thereof | |
| CN101343327A (en) | Antiviral protein and uses thereof | |
| Sloots et al. | Recombinant derivatives of the human high‐mobility group protein HMGB2 mediate efficient nonviral gene delivery | |
| CN114560915A (en) | Modified high-titer SARS-CoV-2 pseudovirus | |
| US10000552B2 (en) | TRAIL cell-penetrating peptide-like mutant MuR5 and preparation method thereof | |
| AU2020310380A1 (en) | Complex for intracellular delivery of molecules | |
| CN109055416A (en) | A kind of preparation method of soluble recombinant protein | |
| WO2015163744A1 (en) | Vector for simultaneously analyzing plurality of protein-protein interactions | |
| CN114057861A (en) | Bio-PROTAC artificial protein targeting UBE2C | |
| CN109207488B (en) | Construction method and application of PE38KDEL gene expression plasmid mediated by tumor specific promoter | |
| CN110372780B (en) | Antitumor polypeptide and application thereof in antitumor field | |
| TWI515203B (en) | Nuclear localization signal peptides derived from vp2 protein of chicken anemia virus and uses of said peptides | |
| KR102138153B1 (en) | A Cell penetrating peptide and high throughput screening method thereof | |
| CN109942715A (en) | A kind of recombination fusion protein of targeting therapy on tumor and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200717 |